>>Signaling Pathways>> Others>>(R)-Oxiracetam

(R)-Oxiracetam

Catalog No.GC34991

(R)-옥시라세탐은 방향성 약물 옥시라세탐의 (R)-거울상 이성질체입니다. Oxiracetam (ISF 2522)은 racetam 계열의 방향성 약물 및 각성제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

(R)-Oxiracetam Chemical Structure

Cas No.: 68252-28-8

Size 가격 재고 수량
5mg
US$130.00
재고 있음
10mM (in 1mL Water)
US$142.00
재고 있음
50mg
US$732.00
재고 있음
100mg
US$1,294.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

(R)-Oxiracetam is the (R)-enantiomer of the nootropic drug oxiracetam. Oxiracetam (ISF 2522) is a nootropic drug of the racetam family and stimulant.IC50 value:Target: nootropic drugOxiracetam (ISF 2522) is a nootropic drug of the racetam family and stimulant.[1][2] Several animal studies suggest that the substance is safe even when high doses are consumed for a long period of time.[medical citation needed] However, the mechanism of action of the racetam drug family is still a matter of research. Oxiracetam is not approved by Food and Drug Administration for any medical use in the United States.

[1]. Malykh AG, et al. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs. 2010 Feb 12;70(3):287-312. [2]. Valzelli L, et al. Difference in learning and retention by Albino Swiss mice. Part III. Effect of some brain stimulants. Methods Find Exp Clin Pharmacol. 1986 Jun;8(6):337-41.

리뷰

Review for (R)-Oxiracetam

Average Rating: 5 ★★★★★ (Based on Reviews and 40 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (R)-Oxiracetam

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.